Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature

详细信息    查看全文

• 作者：Diana Castagna ; David C. Budd ; Simon J. F. Macdonald ; Craig Jamieson ; Allan J. B. Watson
• 刊名：Journal of Medicinal Chemistry
• 出版年：2016
• 出版时间：June 23, 2016
• 年：2016
• 卷：59
• 期：12
• 页码：5604-5621
• 全文大小：1365K
• 年卷期：0
• ISSN：1520-4804

文摘

The autotaxin–lysophophatidic acid (ATX–LPA) signaling pathway is implicated in a variety of human disease states including angiogenesis, autoimmune diseases, cancer, fibrotic diseases, inflammation, neurodegeneration, and neuropathic pain, among others. As a result, ATX–LPA has become of significant interest within both the industrial and the academic communities. This review aims to provide a concise overview of the development of novel ATX inhibitors, including the disclosure of the first ATX clinical trial data.